Highlights of drug - and herb- induced liver injury in the literature from 2016: how best to translate new information into clinical practice?

References

• Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015 Jun;148(7):1340–1352. ​
   PubMed Web of Science ®Google Scholar
• Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the US Drug‐Induced Liver Injury Network. Hepatology. 2014;60(4):1399–1408.
   PubMed Web of Science ®Google Scholar
• Bessone F, Hernandez N, Lucena MI, et al. The Latin American DILI registry experience: a successful ongoing collaborative strategic initiative. Int J Mol Sci. 2016;17(3):313.
   PubMed Web of Science ®Google Scholar
• Liu C, Fan H, Li Y, et al. Research advances on hepatotoxicity of herbal medicines in China. Biomed Res Int. 2016;2016:1–14.
   Google Scholar
• Oh SJ, Cho JH, Son CG. Systematic review of the incidence of herbal drug-induced liver injury in Korea. J Ethnopharmacol. 2015;159:253–256.
   PubMed Web of Science ®Google Scholar
• Teschke R, Schwarzenboeck A, Eickhoff A, et al. Clinical and causality assessment in herbal hepatotoxicity. Expert Opin Drug Saf. 2013;12(3):339–366.
   PubMed Web of Science ®Google Scholar
• Teschke R, Schulze J, Eickhoff A, et al. Mysterious Hawaii liver disease case—naproxen overdose as cause rather than OxyELITE Pro? J Liver Clin Res. 2015;2:1013.
   Google Scholar
• Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993;46(11):1323–1330.
   PubMed Web of Science ®Google Scholar
• Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46(11):1331–1336.
   PubMed Web of Science ®Google Scholar
• Clarke JI, Dear JW, Antoine DJ. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety–false dawn or new horizon? Expert Opin Drug Saf. 2016;15(5):625–634.
   PubMed Web of Science ®Google Scholar
• Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2015;17(1):14.
   PubMed Web of Science ®Google Scholar
• In brief: hepatitis B reactivation with direct-acting antiviral drugs for hepatitis C. [cited 2017 Feb 23]. Available from: http://secure.medicalletter.org/w1506b
   Google Scholar
• Fredj NB, Gam R, Kerkni E, et al. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients. Pharmacogenomics J. 2016 Apr 19;1:6. ​
   PubMed Web of Science ®Google Scholar
• Jung JA, Kim TE, Lee H, et al. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. Drug Des Devel Ther. 2015;9:5433.
   PubMed Web of Science ®Google Scholar
• Guaoua S, Ratbi I, El Bouazzi O, et al. NAT2 genotypes in Moroccan patients with hepatotoxicity due to antituberculosis drugs. Genet Test Mol Biomarkers. 2016;20(11):680–684.
   PubMed Web of Science ®Google Scholar
• Karvellas CJ, Speiser JL, Tremblay M, et al. Elevated FABP1 serum levels are associated with poorer survival in acetaminophen‐induced acute liver failure. Hepatology. 2017 Mar 1;65(3):938–949. ​
   Web of Science ®Google Scholar
• Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. Philadelphia:Lippincott Williams & Wilkins; 1999. ​
   Google Scholar
• Teschke R, Danan G. Diagnosis and management of drug-induced liver injury (DILI) in patients with pre-existing liver disease. Drug Safety. 2016;39(8):729–744.
   PubMed Web of Science ®Google Scholar
• Björnsson ES. Hepatotoxicity by drugs: the most common implicated agents. Int J Mol Sci. 2016;17(2):224.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology. 2008;135(6):1924–1934.
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–1425.
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology. 2016;63(2):590–603.
   PubMed Web of Science ®Google Scholar
• Heidemann LA, Navarro VJ, Ahmad J, et al. Severe acute hepatocellular injury attributed to OxyELITE Pro: a case series. Dig Dis Sci. 2016;61(9):2741–2748.
   PubMed Web of Science ®Google Scholar
• FDA. [cited 2017 Feb 23]. Available from: Website. http://www.fda.gov/food/recallsoutbreaksemergencies/outbreaks/ucm370849.htm
   Google Scholar
• Teschke R, Eickhoff A. The Honolulu Liver disease cluster at the medical center: its mysteries and challenges. Int J Mol Sci. 2016;17(4):476.
   PubMed Web of Science ®Google Scholar
• Teschke R, Schwarzenboeck A, Frenzel C, et al. The mystery of the Hawaii liver disease cluster in summer 2013: a pragmatic and clinical approach to solve the problem. Ann Hepatology. 2016;15:1.
   Web of Science ®Google Scholar
• Björnsson ES, Gu J, Kleiner DE, et al. Azathioprine and 6-mercaptopurine-induced liver injury: clinical features and outcomes. J Clin Gastroenterol. 2017;51(1):63–69.
   PubMed Web of Science ®Google Scholar
• deLemos AS, Ghabril M, Rockey DC, et al. Amoxicillin–clavulanate-induced liver injury. Dig Dis Sci. 2016;61(8):2406–2416.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Brillant P, Schiff ER. Amoxicillin-clavulanate potassium-associated cholestasis. Gastroenterology. 1989;96(4):1135–1141.
   PubMed Web of Science ®Google Scholar
• Schmeltzer PA, Kosinski AS, Kleiner DE, et al. Liver injury from nonsteroidal anti‐inflammatory drugs in the United States. Liver International. 2016 Apr 1;36(4):603–609. ​
   PubMed Web of Science ®Google Scholar
• Bohm M, Vuppalanchi R, Chalasani N. Febuxostat‐induced acute liver injury. Hepatology. 2016;63(3):1047–1049.
   PubMed Web of Science ®Google Scholar
• [Cited 2017 Feb 23]. Liver Tox Database: Livertox.nim.nih.gov. ​
   Google Scholar
• Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug‐induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014 Feb 1;59(2):661–670.
   PubMed Web of Science ®Google Scholar
• Stine JG, Northup PG. Autoimmune-like drug-induced liver injury: a review and update for the clinician. Expert Opin Drug Metab Toxicol. 2016;12(11):1291–1301.
   PubMed Web of Science ®Google Scholar
• de Boer YS, Kosinski AS, Urban TJ, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol. 2017;15(1):103–112.
   PubMed Web of Science ®Google Scholar
• Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010 Jun 1;51(6):2193–2213.
   PubMed Web of Science ®Google Scholar
• Spanish DILI Registry. [cited 2017 Feb 23]. Available from: https://www.spanishdili.uma.es/ ​
   Google Scholar
• Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–521.
   PubMed Web of Science ®Google Scholar
• Stephens C, Castiella A, Gomez-Moreno EM, et al. Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis: the influence of human leucocyte antigen alleles. Pharmacogenet Genomics. 2016;26(9):414–422.
   PubMed Web of Science ®Google Scholar
• Levesque H, Manchon ND, Moore N, et al. Fulminant hepatitis due to cyproterone acetate. The Lancet. 1989;333(8631):215–216.
   Google Scholar
• Kim JH, Yoo BW, Yang WJ. Hepatic failure induced by cyproterone acetate: a case report and literature review. Can Urol Assoc J. 2014;8(5–6):E458.
   PubMedGoogle Scholar
• Bessone F, Lucena MI, Roma MG, et al. Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid‐responsive hepatitis: report of 22 cases. Liver Int. 2016;36(2):302–310.
   PubMed Web of Science ®Google Scholar
• Douros A, Bronder E, Andersohn F, et al. Drug‐induced liver injury: results from the hospital‐based Berlin case–control surveillance study. Br J Clin Pharmacol. 2015;79(6):988–999.
   PubMed Web of Science ®Google Scholar
• Douros A, Bronder E, Andersohn F, et al. Herb-induced liver injury in the berlin case-control surveillance study. Int J Mol Sci. 2016;17(1):114.
   Web of Science ®Google Scholar
• Valdivia-Correa B, Gómez-Gutiérrez C, Uribe M, et al. Herbal medicine in Mexico: a cause of hepatotoxicity. A critical review. Int J Mol Sci. 2016;17(2):235.
   PubMed Web of Science ®Google Scholar
• Pantano F, Tittarelli R, Mannocchi G, et al. Hepatotoxicity induced by “the 3Ks”: kava, Kratom and Khat. Int J Mol Sci. 2016;17(4):580.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Niu M, Chen J, et al. Hepatobiliary and pancreatic: comparison between Chinese herbal medicine and Western medicine‐induced liver injury of 1985 patients. J Gastroenterol Hepatol. 2016;31(8):1476–1482.
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Hayashi PH, Barnhart H, et al. Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury. Am J Gastroenterol. 2015;110:1450–1459.
   PubMed Web of Science ®Google Scholar
• Medina-Caliz I, Robles-Diaz M, Garcia-Muñoz B, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol. 2016;65(3):532–542.
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. [cited 2017 May 10]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm468634.htm ​
   Google Scholar
• The Medical Letter on Drugs and Therapeutics. In Brief: Hepatic Injury with Hepatitis C Drugs. [cited 2017 Feb 23]. Available from: http://secure.medicalletter.org/w1481e ​
   Google Scholar
• HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. [cited 2017 Jun 16]. Available from: http://hcvguidelines.org/ ​
   Google Scholar
• Hasin Y, Shteingart S, Dahari H, et al. Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: case report. World J Hepatol. 2016;8(20):858.
   PubMedGoogle Scholar
• Stine JG, Intagliata N, Shah NL, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci. 2015;60(4):1031–1035.
   PubMed Web of Science ®Google Scholar
• Dyson JK, Hutchinson J, Harrison L, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol. 2016;64(1):234–238.
   PubMed Web of Science ®Google Scholar
• Ou P, Li F, Chen J. New direct-acting antiviral agents can be hepatotoxic in patients with hepatitis C virus infection and decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2016;14(11):1669–1671.
   PubMed Web of Science ®Google Scholar
• Welker MW, Luhne S, Lange CM, et al. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. J Hepatol. 2016;64(4):790–799.
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH. Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C. J Hepatol. 2016;64(4):763–765.
   PubMed Web of Science ®Google Scholar
• Drug-Induced Liver Injury (DILI) Conference XVI. How Should Liver Injury and Dysfunction Caused by Drugs Be Measured, Evaluated, and Acted Upon in Clinical Trials?[cited 2017 Feb 23]. Available from: https://www.aasld.org/sites/default/files/documents/DILI/2016/2016MeetingAgenda.pdf ​
   Google Scholar
• Chhatwal J, Samur S, Kues B, et al. Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology. 2017 Mar 1;65(3):777–788. ​
   Google Scholar
• Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol. 1998;36(7):2084–2086.
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. [ cited 2017May 10]. Available from: https://www.fda.gov/downloads/Drugs/DrugSafety/UCM523499.pdf ​
   Google Scholar
• Sulkowski MS, Chuang WL, Kao JH, et al. No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection. Clin Infect Dis. 2016;63(9):1202–1204.
   PubMed Web of Science ®Google Scholar
• De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27–30.
   PubMed Web of Science ®Google Scholar
• Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis. 2015Jun 16;61(8):1304–1306. ​
   Web of Science ®Google Scholar
• Ende AR, Kim NH, Yeh MM, et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015;9(1):164.
   PubMedGoogle Scholar
• Takayama H, Sato T, Ikeda F, et al. Reactivation of hepatitis B virus during interferon‐free therapy with daclatasvir and asunaprevir in patient with hepatitis B virus/hepatitis C virus co‐infection. Hepatol Res. 2016 Apr 1;46(5):489–491. ​
   Web of Science ®Google Scholar
• Pillai AA, Anania FA, Pearlman BL. Caution: reactivation of hepatitis B during hepatitis C treatment with direct-acting antiviral therapy. Am J Gastroenterol. 2016;111(12):1854–1856.
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. [cited 2017 Feb 23]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm ​
   Google Scholar
• Bersoff-Matcha SJ, Cao K, Jason M, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: A review of cases reported to the US Food and Drug Administration adverse event reporting systemhbv-R associated with DAA therapy for chronic HCV. Ann Intern Med. 2017 Jun 6;166(11):792–798. ​
   PubMed Web of Science ®Google Scholar
• Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology. 2010;51(3):759–766.
   PubMed Web of Science ®Google Scholar
• Liu CH, Liu CJ, Su TH, et al. Hepatitis B virus reactivation in patients receiving interferon-free direct-acting antiviral agents for chronic hepatitis C virus infection. InOpen Forum Infectious Diseases. 2017 Feb 11;4(1):ofx028. US: Oxford University Press.
   PubMed Web of Science ®Google Scholar
• Björnsson ES. Hepatotoxicity of statins and other lipid‐lowering agents. Liver Int. 2017;37:173–178.
   PubMed Web of Science ®Google Scholar
• Clarke AT, Johnson PC, Hall GC, et al. High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD cohort. PloS One. 2016;11(3):e0151587.
   PubMed Web of Science ®Google Scholar
• El Bouazzi O, Hammi S, Bourkadi JE, et al. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors. Pan Afr Med J. 2016Nov 16;25:167. ​
   Web of Science ®Google Scholar
• Sun Q, Zhang Q, Gu J, et al. Prevalence, risk factors, management, and treatment outcomes of first‐line antituberculous drug‐induced liver injury: a prospective cohort study. Pharmacoepidemiol Drug Saf. 2016 Aug;25(8):908–917. ​
   Web of Science ®Google Scholar
• Araújo-Mariz C, Lopes EP, Acioli-Santos B, et al. Hepatotoxicity during treatment for tuberculosis in people living with HIV/AIDS. PloS One. 2016;11(6):e0157725.
   PubMed Web of Science ®Google Scholar
• Makhlouf HA, Helmy A, Fawzy E, et al. A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases. Hepatol Int. 2008;2(3):353.
   PubMed Web of Science ®Google Scholar
• Du H, Chen X, Fang Y, et al. Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis. Mol Biol Rep. 2013;40(5):3591–3596.
   PubMed Web of Science ®Google Scholar
• Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med. 2002;166(7):916–919.
   PubMed Web of Science ®Google Scholar
• Wattanapokayakit S, Mushiroda T, Yanai H, et al. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients. Int J Tuberculosis Lung Dis. 2016;20(10):1364–1369.
   PubMed Web of Science ®Google Scholar
• Mushiroda T, Yanai H, Yoshiyama T, et al. Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients. Human Genome Variation. 2016;3:16014.
   PubMedGoogle Scholar
• Yuliwulandari R, Susilowati RW, Wicaksono BD, et al. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis. J Hum Genet. 2016;61(6):533–537.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhu X, Li Y, et al. Correlation of CpG Island methylation of the cytochrome P450 2E1/2D6 genes with liver injury induced by anti-tuberculosis drugs: a nested case-control study. Int J Environ Res Public Health. 2016;13(8):776.
   PubMed Web of Science ®Google Scholar
• Heinrich M, Zembrzuski V, Ota M, et al. Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil. Tuberculosis. 2016;31(101):15–24.
   Google Scholar
• Petros Z, Lee TM, Takahashi A, et al. Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity. BMC Genomics. 2016;17(1):755.
   PubMedGoogle Scholar
• Hillman L, Gottfried M, Whitsett M, et al. Corrigendum: clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury. Am J Gastroenterol. 2016;111(10):1504.
   PubMed Web of Science ®Google Scholar
• Roberts DW, Lee WM, Hinson JA, et al. An immunoassay to rapidly measure acetaminophen protein adducts accurately identifies patients with acute liver injury or failure. Clin Gastroenterol Hepatol. 2017;15(4):555–562.
   PubMed Web of Science ®Google Scholar
• Alonso EM, James LP, Zhang S, et al. Pediatric Acute Liver Failure Study Group. Acetaminophen adducts detected in serum of pediatric patients with acute liver failure. J Pediatr Gastroenterol Nutr. 2015;61(1):102.
   PubMed Web of Science ®Google Scholar
• Vliegenthart AD, Kimmitt RA, Seymour JH, et al. Circulating acetaminophen metabolites are toxicokinetic biomarkers of acute liver injury. Clin Pharmacol Ther. 2017 Apr;101(4):531–540. ​
   PubMed Web of Science ®Google Scholar
• Teschke R, Schulze J, Eickhoff A, et al. Drug induced liver injury: can biomarkers assist RUCAM in causality assessment? Int J Mol Sci. 2017;18(4):803.
   Web of Science ®Google Scholar
• Russo MW, Steuerwald N, Norton HJ, et al. Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. Liver Int. 2017 May;37(5):757–764. ​
   PubMed Web of Science ®Google Scholar
• Mikus M, Drobin K, Gry M, et al. Elevated levels of circulating CDH5 and FABP1 in association with human drug‐induced liver injury. Liver Int. 2017;37(1):132–140.
   PubMed Web of Science ®Google Scholar
• Chen M, Borlak J, Tong W. A model to predict severity of drug‐induced liver injury in humans. Hepatology. 2016;64(3):931–940.
   PubMed Web of Science ®Google Scholar
• Chan R, Benet LZ. Evaluation of DILI predictive hypotheses in early drug development. Chem Res Toxicol. 2017 Mar 15;30(4):1017–1029.
   PubMed Web of Science ®Google Scholar
• Raschi E, De Ponti F. Drug-induced liver injury: towards early prediction and risk stratification. World J Hepatol. 2017 Jan 8;9(1):30–37.
   PubMed Web of Science ®Google Scholar
• Shi Q, Niu J, Huang X, et al. Do muscle enzyme changes forecast liver injury in polymyositis/dermatomyositis patients treated with methylprednisolone and methotrexate? Ann Clin Lab Sci. 2016;46(3):266–269.
   PubMed Web of Science ®Google Scholar
• Teschke R, Eickhoff A, Schulze J, et al. Petadolex®, a herbal extract for migraine prophylaxis with spontaneous case reports of disputed liver injury: robust causality evaluation by RUCAM, the roussel uclaf causality assessment method. Eur J Pharmaceut Med Res. 2016;3(12):154–177.
   Google Scholar
• Lewis JH. Causality assessment: which is best—expert opinion or RUCAM? Clin Liver Dis. 2014 Jul 1;4(1):4–8.
   Google Scholar
• Chalasani N, Regev A. Drug-induced liver injury in patients with preexisting chronic liver disease in drug development: how to identify and manage? Gastroenterology. 2016;151(6):1046–1051.
   PubMed Web of Science ®Google Scholar
• Teschke R, Danan G. Drug-induced liver injury: is chronic liver disease a risk factor and a clinical issue? Expert Opin Drug Metab Toxicol. 2017;13(4):425–438.
   PubMed Web of Science ®Google Scholar
• Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis–a practical guide. Aliment Pharmacol Ther. 2013;37(12):1132–1156.
   PubMed Web of Science ®Google Scholar
• Nguyen D, Banerjee N, Abdelaziz D, et al. Trainees’ attitudes and preferences toward the use of over the counter analgesics in patients with chronic liver disease. Adv Pharmacoepidemiol Drug Saf. 2014;3(167):1052–2167.
   Google Scholar
• Rossi S, Assis DN, Awsare M, et al. Use of over-the-counter analgesics in patients with chronic liver disease. Drug Safety. 2008;31(3):261–270.
   PubMed Web of Science ®Google Scholar
• Hong YM, Yoon KT, Heo J, et al. The prescription pattern of acetaminophen and non-steroidal anti-inflammatory drugs in patients with liver cirrhosis. J Korean Med Sci. 2016;31(10):1604–1610.
   PubMed Web of Science ®Google Scholar
• Teschke R, Andrade RJ. Drug, herb, and dietary supplement hepatotoxicity. 2016Sep 6;17(9). ​
   Google Scholar
• Hayashi PH. Drug-induced liver injury network causality assessment: criteria and experience in the United States. Int J Mol Sci. 2016;17(2):201.
   PubMed Web of Science ®Google Scholar
• Hayashi PH, Barnhart HX, Fontana RJ, et al. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug‐Induced Liver Injury Network (DILIN). Liver Int. 2015;35(5):1623–1632.
   PubMed Web of Science ®Google Scholar